Effectiveness and Tolerability of LabiaStick#01 in Subjects With Symptomatic Non-hypertrophic Chronic Vulvar Dermatoses

An Open-label Study to Investigate the Effectiveness in Clinical Symptomatic Control and Tolerability of Medical Device LabiaStick#01 in Subjects With Symptomatic Non-hypertrophic Chronic Vulvar Dermatoses

The current study aims to investigate the effectiveness in clinical symptomatic control and tolerability of LabiaStick#01 in women with symptomatic non-hypertrophic chronic vulvar dermatoses.

Study Overview

• Status: Terminated
• Conditions: Chronic Disease of Skin
• Intervention / Treatment: Device: LabiaStick#01

Detailed Description

Vulvar dermatoses are skin disorders that affect the vulva, causing pruritus, irritation and pain. Although the prevalence of these disorders is unknown, it is well accepted that the vulvar symptoms are a common problem for women.

LabiaStick#01 has emollient agents whose main function is to increase the skin hydration, provide physical protection and decrease the symptoms and possibility of recurrence of vulvar dermatoses.

The medical device should be applied once daily, in the evening, after intimal hygiene care.

The primary objective of this study is to evaluate the effectiveness of LabiaStick#01 on the relief of pruritus caused by symptomatic non-hypertrophic chronic vulvar dermatoses.

• Study Type: Interventional
• Enrollment (Actual): 3
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Portugal
  • Porto, Portugal, 4200-319
    • Centro Hospitalar de S. João EPE
  • Vila Nova de Gaia, Portugal, 4400-129
    • Centro Hospitalar Vila Nova de Gaia/Espinho, E.P.E
  • Almada
    • Lisboa, Almada, Portugal, 2805-267
      • Hospital Garcia da Orta, EPE
  • Castelo Branco
    • Covilhã, Castelo Branco, Portugal, 6200-251
      • Centro Hospitalar Cova da Beira EPE
  • Porto
    • Póvoa de Varzim, Porto, Portugal, 4490-405
      • Apomédica - Serviços Médicos Ltd
  • Senhora Da Hora
    • Matosinhos, Senhora Da Hora, Portugal, 4464-513
      • Unidade Local de Saúde de Matosinhos

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Female

Description

Inclusion Criteria:

• Able and willing to give written informed consent.
• Woman, with 18 or more years.
• Diagnosed with symptomatic non-hypertrophic chronic vulvar dermatoses.
• A pruritus score of at least 20 on a 100-mm VAS-PR.
• Willing and able to comply with the study requirements.
• Participant of childbearing potential agrees to remain abstinent or to use an acceptable contraceptive measure for the entire duration of the study.
• Participant not of childbearing potential (e.g., is not sexually active, whose current partner is not of reproductive potential).

Exclusion Criteria:

• Received systemic immunosuppressant therapy (e.g. systemic corticosteroids) within 4 weeks prior to admission.
• Treated with daily topical therapy (e.g. topical corticosteroids, pimecrolimus, and tacrolimus) at the target vulvar area within 2 weeks prior to admission, which in the opinion of the investigator might compromise study results.
• Immunocompromised (e.g., lymphoma, AIDS, Wiskott-Aldrich Syndrome) or have an uncontrolled malignant disease.
• Suffers from systemic or generalized infections (bacterial, viral or fungal).
• Diagnosis of psoriasis, candidiasis, vulvar intraepithelial neoplasia or carcinoma of the vulva.
• Pregnancy or breastfeeding.
• Documented and consistent history of hypersensitivity reactions to similar topical products.
• Any condition that in the opinion of the investigator might prevent the subject from completing the study or interfere with the interpretation of the study results.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: NA
• Interventional Model: SINGLE_GROUP
• Masking: NONE

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: LabiaStick#01; Each participant will have an at least 2-week baseline period followed by a 4-week treatment period with LabiaStick#01.	Device: LabiaStick#01; This medical device has emollient agents whose main function is to increase the skin hydration, provide physical protection and decrease the symptoms and possibility of recurrence of vulvar dermatoses. The medical device should be applied once daily, in the evening, after a gentle washing (plain water with no cleansing products), on the affected non-hairy vulvar area.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Reduction on subject's vulvar pruritus score	Reduction on subject's vulvar pruritus score assessed on a 100-mm Visual Analogue Scale for Pruritus Relief (VAS-PR) following once-daily application of LabiaStick#01, for 4 weeks.	14 days during run-in period and 14 days during treatment period

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Reduction on subject's vulvar burning sensation score	Reduction on subject's vulvar burning sensation score assessed on a 100-mm Visual Analogue Scale (Burning VAS).	During 4 weeks
Clinical Global Impression of Change (CGI-C)		At Visit 3 (28 days after the end of baseline)
Patient Global Impression of Change (PGI-C)		At Visit 3 (28 days after the end of baseline)
Subjects' opinion on the acceptability of the medical device	Subjects' opinion on the acceptability of the medical device (cosmetic acceptability and easiness of use)	At Visit 3 (28 days after the end of baseline)
Need of rescue medication		Up to 6 weeks
Adverse events		Up to 6 weeks

Collaborators and Investigators

• Sponsor: Health Products Research and Development Lda.
• Collaborators: Blueclinical, Ltd.
• Investigators: Principal Investigator: José Martinez de Oliveira, MD, PhD, HPRD

Study record dates

Study Major Dates

• Study Start: September 1, 2015
• Primary Completion (ACTUAL): January 1, 2018
• Study Completion (ACTUAL): January 1, 2018

Study Registration Dates

• First Submitted: September 2, 2015
• First Submitted That Met QC Criteria: September 2, 2015
• First Posted (ESTIMATE): September 4, 2015

Study Record Updates

• Last Update Posted (ACTUAL): February 22, 2018
• Last Update Submitted That Met QC Criteria: February 20, 2018
• Last Verified: February 1, 2018

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Disease Attributes; Chronic Disease; Skin Diseases
• Other Study ID Numbers: LF-01-01